Apr. 29, 2010
On April 30, 2010 Tasly Ginna Biotechnology (Tianjin) Co., Ltd. received SFDA approval for its influenza virus subunit vaccine.
Due to technical difficulties, Tasly is only the second domestic company to date that managed to achieve SFDA approval for a subunit vaccine.
According to global statistics, the annual number of influenza cases ranges between 120 million to 600 million cases. Global vaccine sales are expected to reach $3.7 billion by 2010. However, the worldwide capacity for influenza vaccine production reaches only 2.8 to 3.0 million doses per year, just 14% of the actual global demand. The growth opportunities for this market are evident. In China, influenza annually occurs in about 8% of the general population – roughly 100 million cases per year.